Skip to main content
. 2021 Feb 23;39(12):1317–1328. doi: 10.1200/JCO.20.01366

TABLE 3.

TEAEs During the Treatment Period in the Safety Population (≥ 15% Any Grade and Adverse Events of Interest)

graphic file with name jco-39-1317-g007.jpg